Evidence mapPaperPMID 31073128Full record

ReviewNature reviews. Disease primers2019

Dilated cardiomyopathy.

Heinz-Peter Schultheiss, DeLisa Fairweather, Alida L P Caforio, Felicitas Escher, Ray E Hershberger, Steven E Lipshultz, Peter P Liu, Akira Matsumori, Andrea Mazzanti, John McMurray and 1 more

2 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Disease primers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 389 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
389citing papers in PubMed, 4 pooled it
38.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05837143 early_phase1unknown statusnot on this mapstarted 2023, after this paper: background citation

An Exploratory Clinical Study of JV001 in the Treatment of Patients With Heart Failure Due to Dilated Cardiomyopathy (Telomere Recapping to Restore Mitochondrial Biogenesis Study for Dilated Cardiomyopathy)

TypeinterventionalSponsorShanghai East HospitalRan2023 to 2025Enrolled12ConditionsHeart Failure, Dilated CardiomyopathyArmsJV001
NCT07536880 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Effect of Sildenafil on Left Ventricular Function in Pediatric Patients With Primary Dilated Cardiomyopathy Prospective Cohort Study

TypeobservationalSponsorAssiut UniversityRan2026 to 2027Enrolled70ConditionsCardiomyopathy, Dilated
3 · Its place in the literature

Who cites it

389 citing papers in PubMed, 4 syntheses or guidelines pooled it, 651 citations in OpenAlex.

  1. Revisiting Secondary Dilative Cardiomyopathy.International journal of molecular sciences · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. From inflammation to inheritance: rethinking myocarditis as the first signal of desmosomal cardiomyopathy.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Microstructural disease and hypoperfusion in dilated cardiomyopathy underpin midwall septal fibrosis.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2026
    Article
  20. Article

329 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 6 countries.

Heinz-Peter SchultheissInstitute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany. heinz-peter.schultheiss@charite.de.
DeLisa FairweatherMayo Clinic, Department of Cardiovascular Medicine, Jacksonville, FL, USA. Fairweather.DeLisa@mayo.edu.
Alida L P CaforioDivision of Cardiology, Department of Cardiological Thoracic and Vascular Sciences and Public Health, University of Padua, Padova, Italy.
Felicitas EscherInstitute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany.
Ray E HershbergerDivisions of Human Genetics and Cardiovascular Medicine in the Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.
Steven E LipshultzDepartment of Pediatrics, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
Peter P LiuUniversity of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Akira MatsumoriClinical Research Center, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Andrea MazzantiDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
John McMurrayBritish Heart Foundation (BHF) Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Silvia G PrioriDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
University of Pavia · ITBritish Heart Foundation · GBCS Diagnostics · DEGerman Centre for Cardiovascular Research · DEJacksonville College · USJacobs (United States) · USKyoto Medical Center · JPThe Ohio State University · USUniversity of Ottawa · CAUniversity of Padua · IT

Funding

NHLBI NIH HHS R01 HL111938NIAID NIH HHS R21 AI145356NIEHS NIH HHS R21 ES024414
6 · The paper itself

Abstract

Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by left ventricular or biventricular dilation and impaired contraction that is not explained by abnormal loading conditions (for example, hypertension and valvular heart disease) or coronary artery disease. Mutations in several genes can cause DCM, including genes encoding structural components of the sarcomere and desmosome. Nongenetic forms of DCM can result from different aetiologies, including inflammation of the myocardium due to an infection (mostly viral); exposure to drugs, toxins or allergens; and systemic endocrine or autoimmune diseases. The heterogeneous aetiology and clinical presentation of DCM make a correct and timely diagnosis challenging. Echocardiography and other imaging techniques are required to assess ventricular dysfunction and adverse myocardial remodelling, and immunological and histological analyses of an endomyocardial biopsy sample are indicated when inflammation or infection is suspected. As DCM eventually leads to impaired contractility, standard approaches to prevent or treat heart failure are the first-line treatment for patients with DCM. Cardiac resynchronization therapy and implantable cardioverter-defibrillators may be required to prevent life-threatening arrhythmias. In addition, identifying the probable cause of DCM helps tailor specific therapies to improve prognosis. An improved aetiology-driven personalized approach to clinical care will benefit patients with DCM, as will new diagnostic tools, such as serum biomarkers, that enable early diagnosis and treatment.

Indexed as

AutoimmunityCardiac Resynchronization TherapyCardiomyopathy, DilatedEchocardiographyElectrocardiographyHeart FailureHumansInflammationMagnetic Resonance ImagingPrognosisQuality of LifeSex Factors

Identifiers

PMID31073128
PMCPMC7096917
OpenAlexW4211051044

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.